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Abstract 
  To determine the clinical efficacy of combined vaccination with 23-valent 
pneumococcal vaccine (PV) and influenza vaccine (IV) against pneumonia and acute 
exacerbation of chronic lung diseases (CLD), we conducted an open-label, randomized, 
controlled study among 167 adults with CLD over a 2 year period. Subjects were 
randomly assigned to a PV+IV group (n=87) or an IV group (n=80), respectively. The 
number of patients with CLD experiencing infectious acute exacerbation (P=0.022), but 
not pneumonia (P=0.284), was significantly lower in the PV+IV group compared with 
the IV group. When these subjects were divided into subgroups, an additive effect of PV 
with IV in preventing infectious acute exacerbation was significant only in patients with 
chronic obstructive pulmonary diseases (P=0.037). In patients with CLD, the 
Kaplan-Meier survival curves demonstrated a significant difference for infectious acute 
exacerbation (P=0.016) between the two groups. An additive effect of PV with IV on 
infectious acute exacerbation was found during the first year after vaccination 
(P=0.019), but not during the second year (P=0.342), and was associated with 
serotype-specific immune response in sera of these patients who used PV during the 
same period.  
 
Keywords: pneumococcal vaccine, influenza vaccine, acute exacerbation, chronic lung 
diseases, chronic obstructive pulmonary diseases
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Introduction  
    Acute exacerbation frequently occurs among patients with chronic lung diseases 
(CLD), such as chronic obstructive pulmonary disease (COPD) and sequelae of 
pulmonary tuberculosis (SPTB)[1,2]. Morbidity, mortality and health-care costs of these 
patients largely result from on acute exacerbations [3]. Acute exacerbations are primarily 
triggered by bacterial or viral pathogens in COPD and SPTB. While Streptococcus 
pneumoniae (S. pneumoniae) is the most commonly identified cause of 
community-acquired pneumonia (CAP) by accounting for 16.5 to 38.9% of CAP among 
adults [4,5], this pathogen is also responsible for 8 to 25 % of acute exacerbation in 
patients with CLD or COPD, which makes it a major bacterial pathogen [2,6,7]. Viral 
pathogens are also capable of inducing acute exacerbation of COPD, and the influenza 
virus was frequently detected in 5 to 29% of exacerbation of COPD [8,9].  
  Since antibodies to pneumococcal capsular polysaccharide (PPS) and its complement 
provide protection against S. pneumoniae with homologous or cross-reactive capsular 
serotypes [10], pnemococcal polysaccharide vaccine (PV) is effective for preventing 
invasive pneumococcal diseases in patients with chronic illness, such as CLD. PV is, 
therefore, recommended for these patients [11-13]. Although the previous studies 
reported that PV is not effective in preventing pneumonia or acute exacerbation in 
patients with COPD [14-16], a recent, prospective study demonstrated an effect of PV in 
preventing pneumonia in such patients with aged less than age of 65 years of age with 
severe airflow obstruction [17]. In addition, a retrospective study previously reported the 
additive effects of PV with influenza vaccine (IV) in the reduction of hospitalization 
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stays and death among elderly persons with CLD [18,19]. Although a large-scale 
prospective study demonstrated the additive effects of PV and IV in reducing hospital 
mortality due to pneumonia among elderly persons [20], no prospective study has been 
conducted to find the additive effects of PV combined IV for preventing pneumonia or 
acute exacerbation in patients with CLD. This open-label, randomized, controlled study 
was designed to determine whether PV and IV combined are superior to IV alone in 
preventing pneumonia or acute exacerbation among patients with CLD. 
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2.Materials and methods 
2.1 Study design 
 For this study, 191 patients with CLD in a stable condition were enrolled after 
providing written informed consent at the respiratory clinic of 13 hospitals in the district 
of Kyushu and Okinawa, Japan between November 2001 and April 2002. All potentially 
eligible subjects (at least twice as many as the enrolled cases) were contacted by the 
members of the Pneumococcal Vaccine Trialist Group, belonging to one of these 
hospitals. As the study investigators, these doctors had a role in selecting the subjects 
for the study enrollment. Inclusion criteria were patients with CLD who previously 
experienced acute exacerbations, were able to comply with a schedule of monthly 
clinical visits and were between 40 and 80 years of age. Patients who were pregnant or 
had immunocompromised conditions such as active malignant diseases, renal 
insufficiency in dialysis or HIV infection, hypogammaglobulinemia or anatomical or 
functional asplenia and who had previously received 23-valent PV (Pneumovax, Banyu, 
Japan) were excluded. The enrollees were randomly assigned in equal proportion to 
either the group receiving PV and IV (The Chemo-Sero-Therapeutic Research Institute, 
Kumamoto, Japan) or IV alone. By sealed envelope, each study site was randomly 
allocated either 10 or 20 cases. Equal numbers of sealed envelopes each containing a 
card indicating either the PV+IV group or the IV group were prepared, and each study 
participant chose an envelope. This vaccine allocation was done by the study 
investigators. In addition, the doctors who screened the subjects also conducted the 
exclusions and enrollments. 
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While the participants in the PV+IV group were separately immunized with 0.5 ml of 
PV and 0.5 ml of IV on separate occasions in one-month intervals, the participants in 
the IV group were immunized with 0.5 ml of IV alone. All participants received IV once 
in both the 2001/2002 and 2002/2003 seasons. For this study, our group used a trivalent, 
split-virion, influenza vaccine, containing A/NewCaledonia/20/99H1N1, 
A/Panama/2007/99H3N2, and B/Johannesburg/5/99 for the 2001/2002 season; and for 
the 2002/2003 season, the study was conducted using vaccine containing 
A/NewCaledonia/20/99H1N1, A/Panama/2007/99H3N2, and B/Guangdong/7/97.  
 Demographic data were obtained from each participant at the time of enrollment. All 
participants were examined, typically once a month, at each hospital by physicians who 
were the members of the Pneumococcal Vaccine Trialist Group at each study hospital in 
the Kyushu and Okinawa districts. Patients were also asked to visit each study hospital 
for examination by a study physician, if they developed a fever, cough and sputum, or 
experienced breathlessness during the 2-year follow-up period.  
 To monitor the concentrations of anti-PPS IgG, serum samples were collected from the 
patients of the PV+IV group immediately before and at 1 month, 6 months, 1 year, and 2 
years after the initial pneumococcal vaccination. Separated sera were stored frozen at 
–80℃ until used. All studies described herein were approved by the institutional review 
board of each institution. 
 
2.2 Study population 
One hundred and ninety-one patients with CLD were assigned to either the PV+IV 
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group (n=94) or to the IV group (n=97) (Fig. 1). During 2-year follow-up period, 2 and 
11 subjects were lost from the PV+IV group and IV groups, respectively. In addition, an 
early termination of follow-up occurred for 5 subjects for the PV+IV group and for 6 
subjects in the IV group because they wanted to withdraw from the study. Subsequently, 
87 subjects in the PV+IV group and 80 subjects in the IV group completed the analysis.  
 
2.3 Outcome measures 
  The outcome measured was recorded as either the time to the first episode of 
pneumonia or to acute exacerbation after the enrollment in this study. A pneumonia 
diagnosis was based on either clinical symptoms (cough, sputum or fever) plus 
increased white blood cell counts or serum C-reactive protein, and the appearance of a 
new infiltration on a chest radiograph [21]. Acute exacerbation in CLD was defined by 
criteria as previously described [22]: 1) increased dyspnea, 2) increased sputum volume, 
and 3) increased sputum purulence, and 4) absence of newly appeared infiltration on a 
chest radiograph. Acute exacerbation was diagnosed when two of the three respiratory 
symptoms existed or when one of these and one of additional symptoms, such as a fever 
without any other causes or increased cough was present [23]. When the laboratory 
examinations revealed an increase in their white blood cell counts or serum C-reactive 
protein, in addition to the clinical symptoms of acute exacerbation, patients were 
diagnosed as infectious acute exacerbation, and were therefore classified into one of two 
categories: either infectious or non-infectious acute exacerbation. Furthermore, when S. 
pneumoniae was isolated from purulent sputum in cases of acute exacerbation, patients 
 7
were diagnosed as pneumococcal acute exacerbation as a subcategory of infectious 
acute exacerbation. 
 
2.4 Measurement of anti-PPS IgG 
 Serum samples for serotype-specific IgG were available from only 35 of 87 patients 
with CLD in the PV+IV group for all intervals-1 month, 6 months, 1 year, and 2 years. 
7 subjects died during the two-year period, and 45 of the remaining subjects lacked at 
least one serum sample from the time interval at either 6 months, 1 year or 2 years. The 
concentrations of serotype-specific IgG were measured as previously described 
elsewhere [24]. The US reference pneumococcal antiserum (89-SF), courtesy of Dr. 
Carl Frasch, was adsorbed to CWPS, but all other samples were adsorbed to CWPS (5 
μg/ml) and 22F PPS (10 μg/ml) [25]. Serotype-specific IgG was determined for the four 
serotypes (6B, 14, 19F and 23F) that are the most prevalent among adult patients with 
pneumococcal infections in the US and Japan [5, 26]. 
 
2.4 Statistical analysis 
  The case numbers of patients with COPD, SPTB, and other CLDs, and the case 
number of patients experiencing pneumonia, infectious acute exacerbation, 
pneumococcal acute exacerbation, and non-infectious acute exacerbation and the case 
numbers of death were compared using a chi-square test. A Kaplan-Meier estimator was 
used to calculate the survival curve for subjects who developed neither pneumonia nor 
infectious or non-infectious acute exacerbation during the 2-years study period. The 
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Cox’s proportional hazard model was used to evaluate the effect of PV on the incidence 
of pneumonia and infectious or non-infectious exacerbation both in the first and second 
one-year. The effects of age (age older than 55 years, 65 years, and older than 75 years) 
and female sex were considered in multivariate analysis. Differences in geometric mean 
concentrations (GMCs) of serotype-specific IgG over time were assessed using the 
Wilcoxon signed-ranks test. An interim target sample size of 82 was chosen to ensure 
that there would be at least an 80% chance to detect a difference of 0.2 (0.2 vs. 0.4) 
episodes per person per year, with a one-sided alpha level of 0.05, in the frequency of 
admission due to pneumonia between groups of PV+IV and IV. Data was considered to 
be statistically significant, if the P values were less than 0.05. 
 
3.Results 
 Ages (mean±SD years) and male sex (%) were 69.0±9.0 and 63.5 for total subjects, 
67.8±9.5 and 69.0 for the PV+IV group, and 70.1±7.4 and 57.5 for the IV group. The 
numbers of patients with three subcategories of CLD (COPD, SPTB and other CLDs) in 
the PV+IV and the IV groups are shown in Table 1. Other CLDs were bronchiectasis 
(n=20; 10 for the PV+IV group and 10 for the IV group), bronchial asthma (n=13, 6 for 
the PV+IV group and 7 for the IV group), pneumoconiosis (n=14, 7 for the PV+IV 
group and 7 for the IV group), interstitial pneumonia (n=9, 3 for the PV+IV group and 6 
for the IV group), diffuse panbronchiolitis (n=5, 4 for the PV+IV group and 1 for the IV 
group), and sarcoidosis (n=1 for the IV group). Fifty-nine subjects received home 
oxygen therapy (HOT) (27 for the PV+IV and 32 for the IV), and 11 subjects (6 for the 
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PV+IV and 5 for the IV) were treated with noninvasive positive pressure ventilation 
(NPPV). While a significant difference was found in the number of patients with SPTB 
between the two groups, no significant difference was found in the number of patients 
with COPD or other CLDs, nor in the number of patients receiving either HOT or 
NPPV.  
  The incidence of pneumonia (0.096 episodes/ patient/ year) with CLD in this study 
was twice as higher as those of previous cohort studies of COPD patients (0.047 to 
0.055 episodes/ patient/ year)[14,17]. No significant difference was found in the number 
of patients developing pneumonia between the PV+IV group and the IV group (Table 1). 
Similarly, no significant difference was found in the Kaplan-Meier survival curves for 
pneumonia between the two groups (P=0.399, Fig 2A).  
  The incidence of acute exacerbation (0.53 episodes/ patient/ year) in this study was 
slightly lower than those of previous studies of COPD patients (0.85-1.08 episodes/ 
patient/ year)[27,28]. No significant difference was found in the number of CLD 
patients with pneumococcal acute exacerbation (P=0.106) or non-infectious acute 
exacerbation (P=0.557) between the two groups (Table 1). In contrast, a significant 
difference was found in the number of CLD patients with infectious acute exacerbation 
(P=0.022) between the two groups (Table 1). The Kaplan-Meier survival curves for 
CLD patients with infectious acute exacerbation (P=0.016, Fig 2B) also demonstrated a 
significant difference between the two groups. However, no significant difference was 
found in the mortality during the 2-years period after vaccination in both groups (Table 
1).  
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  Furthermore, we examined the number of patients experiencing pneumonia and 
infectious or non-infectious acute exacerbation in each subcategory (Table 2). No 
significant difference was found in the number of patients with COPD, SPTB and other 
CLDs experiencing either pneumonia or non-infectious acute exacerbation. In contrast, 
a significant difference was found in the number of patients with COPD experiencing 
infectious acute exacerbation (P=0.037), but not in the number of patients with SPTB 
(P=0.442) or other CLDs (P=0.599). In COPD patients, the Kaplan-Meier survival 
curves for infectious acute exacerbation demonstrated a significant difference between 
the two groups (P=0.041, Fig 3), while no significant difference was found in the 
Kaplan-Meier survival curves for pneumonia (P=0.543) or non-infectious acute 
exacerbation (P=0.426) in COPD patients (data not shown). 
  While neither a univariate nor multivariate analysis demonstrated a significant 
association between any variables and the probability of either pneumonia or 
non-infectious acute exacerbation in either the first or second year, a significant 
association between the receipt of PV and a low probability of infectious acute 
exacerbation was found in patients with CLD in the first year, but not in the second year 
by a single variable analysis (P=0.019) or multivariate analyses (P=0.016, Table 3). No 
significant association was demonstrated between any variable, such as age older than 
55 years, age older than 65 years, age older than 75 years or the female sex and the 
probability for infectious acute exacerbation, in either the first or second year.  
 The GMCs of serotype-specific IgG for four serotypes in sera from the 35 patients 
with CLD during the 2 years after their vaccinations are shown in Table 4. Before 
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vaccination, the GMCs ranged from 2.6 µg/ml for serotype 23F to 5.69 µg/ml for 
serotype 14. One month after vaccination, significant increases in the GMCs of 
serotype-specific IgG were found for all serotypes in all subjects, compared to those 
before vaccination (P<0.01, Table 4). The GMCs of serotype-specific IgG declined 
below pre-vaccination levels at 6 months post-vaccination for types 6B and 19F. In 
contrast, the GMCs of serotype-specific IgG remained above the pre-vaccination levels 
for type 23 F and type 14 at 2 years post-vaccination, although they had declined from 
the immediate post-vaccine levels. Serotype-specific IgG responses to PV, therefore, 
were found primarily in sera during the first year, but not during the second year, 
following vaccination. 
 
4. Discussion 
  This study demonstrated an additive effect of PV with IV in preventing infectious 
acute exacerbation, but not pneumonia or non-infectious acute exacerbation, when 
compared to IV alone in patients with CLD. When theses subjects were divided into 
three subgroups according to their type of CLD, an additive effect of PV with IV in 
preventing infectious acute exacerbation was found only in COPD patients, but not in 
patients with SPTB or other pulmonary diseases. Since no attempt was made to blind the 
clinical assessors to the vaccine allocation in this study, the possibility of the bias on the 
clinical assessment obtained by the investigators can not be dismissed.  
 Although this was an open-label, randomized controlled study on a small scale, the 
enrolled patients with CLD in this study were at a high risk for pneumonia or acute 
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exacerbation. Since pneumococci has a major role in the development of pneumonia 
associated with respiratory viruses such as influenza virus, these viruses contribute to the 
pathogenesis of bacterial pneumonia among children [29]. Other investigators have also 
demonstrated that influenza neuraminidase facilitated bacterial adherence of S. 
pneumoniae, and resulted in secondary bacterial pneumonia in mice [30,31]. Based on 
the interaction between influenza virus and pneumococci on the pathogenesis of 
bacterial pneumonia, an additive or synergistic effect of the combined vaccination with 
PV and IV in preventing pneumococcal pneumonia can be expected.  
 A large prospective study in Sweden reported the additive effects of PV with IV in 
reducing pneumococcal pneumonia as well as invasive pneumococcal diseases, 
compared to no vaccination, among adults aged 65 years or older during the first 6 
months after vaccination [32]. The authors demonstrated the additive effect of PV with 
IV only in reducing the hospital mortality due to pneumonia, compared to a vaccination 
with IV alone or PV alone, at 1-year after vaccination [20]. Another investigator, 
however, did not find an additive effect of PV with IV in preventing pneumococcal 
pneumonia as well as pneumonia, compared to IV alone, among the same population 
during a 2-year period after vaccination [33]. 
  A double-blind, randomized placebo-controlled trial in Thailand recently reported that 
IV was found highly effective in preventing the influenza-related acute respiratory 
illness, but not acute exacerbation or pneumonia, in COPD patients [23]. Since no effect 
of IV was found for preventing acute exacerbation among patients with COPD, our data 
suggests not only the importance of PV in addition to IV among patients with CLD, but 
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also the role of pneumococcal infection in the pathogenesis of acute exacerbation in such 
patients.  
 Although no significant difference was found in the number of patients with 
pneumococcal acute exacerbation between the two groups in this study, a reduced 
number of pneumococcal infections in the PV+IV group may suggest the contribution of 
protective immunity raised by PV in such patients. More importantly, the additive effect 
of PV with IV on infectious acute exacerbation was significant during the first year, but 
not the second year after vaccination. This effect was associated with an immune 
response of serotype-specific IgG to PV, which was prominent in all serotypes during 
the first year.  
  Although the protective concentrations of serotype-specific IgG are not known, most 
of CLD patients showed a level of IgG much higher than the threshold (0.35 μg/ml) that 
predicts protection in infants against invasive disease at a population level after 
immunization with pneumococcal conjugate vaccine in this study [34]. A recent study 
also reported that higher levels of antipneumococcal antibodies did not correlate with 
protection from pneumococcal colonization in patients with COPD [35]. Therefore, the 
question arises as to why an additional increase of IgG in sera is required for preventing 
infectious acute exacerbation in COPD patients. A recent report demonstrated that the 
levels of anti-serotype-1 IgG in bronchoalveolar lavage (BAL) fluid were less than 10 
ng/ml in 25 of 49 HIV-uninfected adults, while the mean level of serotype-1 specific 
IgG in sera of such subjects was 1,608 ng/ml [36]. Thus, the level of specific IgG in the 
neat BAL fluid is at least 161 times lower than that in sera. According to this 
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information and the data of levels of specific IgG in sera of patients with CLD before 
(2.60 to 5.69 μg/ml) and after vaccination (5.26 to 12.63 μg/ml) in this study, the levels 
of specific IgG in BAL fluid are estimated to be less than 35.3 ng/ml before vaccination 
and less than 78.5 ng/ml after vaccination, respectively. Since we found a significant 
effect of PV+IV on infectious acute exacerbation, compared with IV alone, the levels of 
serotype-specific IgG that rise higher than approximately 35 ng/ml in the lower airway 
fluid may be critical for preventing infectious acute exacerbation in patients with COPD.    
   Furthermore, the cost of acute exacerbation on patients with COPD creates a 
significant economic impact [3]. The literatures reports that the estimated costs for 
hospitalization due to acute exacerbation will range from $5,655 to $7,413 in developed 
countries [37-39]. The reduced frequency (27.2%) of acute exacerbation in the PV+IV 
group in this study, compared to the IV group, has significant economic implications for 
patients with COPD. 
   In conclusion, this pilot study demonstrated an additive effect of PV in combination 
with IV on infectious acute exacerbation of patients with COPD. This effect was closely 
associated with serotype-specific immune response to PV that was primarily found 
during the first year after vaccination. Further studies on a larger scale are required to 
investigate the additive effects of PV and IV on the incidence of acute exacerbation in 
COPD patients with various levels of airflow limitations. 
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Figure legends 
Fig. 1. Flow diagram of study patients with chronic lung disease. 
Fig. 2. Kaplan-Meier survival curves for patients with chronic lung diseases (CLD) 
showing the proportion of subjects free from pneumonia (A) and infectious acute 
exacerbation (B) between PV+IV group and IV group during the follow-up period.  
Fig.3. Kaplan-Meier survival curve for patients with chronic obstructive pulmonary 
diseases (COPD) showing the proportion of subjects free from infectious acute 
exacerbation between PV+IV group and IV group during the follow-up period.  
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COPD
Sequelae of 
pulmonary tuberculosis
Other CLDs
24 (27.6) 31(38.8)
33 (37.9) 17 (21.3)
30 (34.5) 32 (40.0)
PV;pneumococcal polysaccharide vaccine, IV; influenza vaccine, COPD; chronic obstructive pulmonary disease.
Acute exacerbations are classified into two categories; infectious and non-infectious acute exacerbation. Infectious
acute exacerbation involves pneumococcal acute exacerbation. 
PV+IV group
n = 87
IV group
n = 80
All subjects
n =167
Table  1.  Demographic features and outcome of patients with chronic lung diseases (CLD) 
55 (32.9)
50 (30.0)
62 (37.1)
No. of patients (%)
Pneumonia
Acute exacerbation
P-value
Subcategories of CLD
Outcome
13 (27.6) 12 (38.8)25 (32.9) 0.284
Infectious
Pneumococcal
32 (36.8) 44 (55.0)76 (45.5) 0.022
1 (1.1) 5 (6.3)6 (3.6) 0.106
Characteristics
Death 7 (8.0) 7 (8.8)14 (8.4) 0.870
0.018
0.461
0.125
9 (10.3) 6 (7.5)15 (9.0)Non-infectious 0.557
Table 2.  Outcome  of patients with COPD, sequelae of pulmonary tuberculosis (SPTB) and other 
chronic lung diseases (CLDs) by vaccine group during 2 years after vaccination
PV；pneumococcal polysaccharide vaccine, IV; influenza vaccine, COPD: chronic obstructive pulmonary diseases.
Acute exacerbations are classified into two categories; infectious and non-infectious acute exacerbation.
       Subcategories of CLD/ Outcome
PV+IV group (n=87) IV group (n=80)
    COPD
                   Pneumonia 6 (6.9) 5 (6.3) 0.615
                   Acute exacerbation
                         Infectious 9 (10.3) 21 (26.3) 0.037
                        Non-infectious 5 (5.7) 2 (2.5) 0.315
  SPTB
                   Pneumonia 3 (3.4) 2 (2.5) 0.218
                   Acute exacerbation
                         Infectious 10 (11.5) 7 (8.7) 0.442
                         Non-infectious 2 (2.3) 3 (3.8) 0.594
  Other CLDs
                    Pneumonia 4 (4.6) 5 (6.3) 0.379
                   Acute exacerbation
                         Infectious 13 (14.9) 16 (20.0) 0.599
                         Non-infectious 2 (2.3) 1 (1.3) 0.616
No. of patients (%)
P value
Period Variables Pneumonia Acute exacerbation,Infectious Acute exacerbation, Non-infectious
Hazard ratio
(95% CI) P value
Hazard ratio
(95% CI) P value
Hazard ratio
(95% CI) P value
First 
year
PV 0.70 (0.31-1.60) 0.402 0.58 (0.37-0.91) 0.019 1.40 (0.50-3.94) 0.522
PV 0.72 (0.32-1.68) 0.452 0.56 (0.35-0.90) 0.016 1.56 (0.54-4.52) 0.411
Age older than 55 y.o. N.A. N.A. 1.02 (0.33-3.12) 0.973 1.97 (0.22-17.4) 0.543
Age older than 65 y.o. 1.05 (0.13-8.52) 0.963 1.15 (0.40-3.27) 0.798 0.33 (0.03-3.76) 0.375
Age older than 75 y.o. 2.63(0.33-20.8) 0.359 0.92 (0.31-2.75) 0.878 1.97 (0.23-17.1) 0.534
Female 0.41(0.14-1.23) 0.113 1.01 (0.63-1.61) 0.972 1.01 (0.33-3.08) 0.982
Second 
year
PV 0.54 (0.13-2.25) 0.397 0.65 (0.26-1.59) 0.342 0.99 (0.28-3.51) 0.987
PV 0.47 (0.11-2.05) 0.314 0.64 (0.25-1.64) 0.351 1.03 (0.26-3.98) 0.969
Age older than 55 y.o. N.A. N.A. 1.11 (0.11-10.76) 0.93 1.36 (0.12-14.97) 0.800
Age older than 65 y.o. 0.31 (0.31-3.05) 0.315 1.46 (0.18-12.1) 0.725 0.36 (0.03-4.29) 0.418
Age older than 75 y.o. 0.60 (0.61-5.77) 0.655 0.81 (0.09-7.73) 0.857 1.09 (0.11-10.78) 0.939
Female 0.22 (0.27-1.84) 0.163 1.18 (0.47-2.99) 0.72 1.18 (0.32-4.37) 0.797
Table 3.  Estimated result of  Cox’s proporti onal hazard model for pneumonia, infectious acut e 
exacerbation, and non-infectious acute exacerbation in patients with chronic lung diseases during the 
first and the second year
N.A.: not applicable, PV: pneumococcal  vaccine. CI: confidence interval
Time GMC of IgG
Serotype point (μg/ml) (95% CI)
6B pre 3.46 (2.51-4.76)
1 month 5.26 (3.78-7.54)*
6 months 3.51 (2.48-5.1)
1 year 3.41 (2.48-4.85)
2 year 2.68 (1.86-3.97)
14 pre 5.69 (4.44-7.03)
1 month 12.63 (8.76-16.61)*
6 months 10.35 (7.17-13.6)*
1 year 8.97 (6.36-11.47)*
2 year 7.76 (5.53-10.07)*
19F pre 4.91 (3.67-6.55)
1 month 7.05 (5.37-9.3)*
6 months 4.81 (3.56-6.49)
1 year 4.60 (3.56-5.93)
2 year 4.58 (3.46-6.05)
23F pre 2.60 (1.97-3.42)
1 month 5.82 (3.71-9.12)*
6 months 4.06 (2.72-6.05)*
1 year 3.56 (2.48-5.1)*
2 year 2.8 (1.9-4.1)
GMC: geometric mean concentration; CI, confidence interval; 
*P<0.01 (for comparison with prevaccination value).
Table 4. Serotype-specific IgG in sera from 35 patients with chronic lung diseases before 1 month, 6 months, 1 year and 2 years after vaccination
